甲状腺眼病的治疗及治疗反应预测因素的研究进展
Research Progress on the Treatment of Thyroid Eye Disease and the Predictors of Treatment Response
DOI: 10.12677/acm.2024.14123132, PDF,   
作者: 蒋 炫, 龙 健*：重庆医科大学附属第一医院内分泌科，重庆
关键词: 甲状腺眼病；糖皮质激素；预测因素；Thyroid Eye Disease； Glucocorticoids； Predictors
摘要: 甲状腺眼病(Thyroid eye disease, TED)是一种累及眼部的自身免疫性疾病。糖皮质激素是中至重度TED的首选药物治疗，治疗不佳者可能导致疾病进展，威胁患者视力，严重者可致残。全面了解TED的治疗方式及影响治疗效果的因素有助于评估疾病预后，尽早采取干预手段以避免患者出现严重的视力损害。本文结合近几年该方面的最新研究对此展开综述。
Abstract: Thyroid eye disease (TED) is an autoimmune disease involving the eye. Glucocorticoids are the preferred pharmacologic treatment for patients with moderate-to-severe TED. Inadequate treatment can lead to disease progression, potentially jeopardizing vision and resulting in disability in severe cases. A comprehensive understanding of the treatment modalities and factors affecting the outcome of TED is helpful in assessing the prognosis of the disease and in taking early interventions to prevent severe visual impairment. This article summarizes the latest research in this area in recent years.
文章引用：蒋炫, 龙健. 甲状腺眼病的治疗及治疗反应预测因素的研究进展[J]. 临床医学进展, 2024, 14(12): 660-664. https://doi.org/10.12677/acm.2024.14123132

参考文献

[1] Hall, A.J.H. and Topliss, D.J. (2022) Medical and Surgical Treatment of Thyroid Eye Disease. Internal Medicine Journal, 52, 14-20. [Google Scholar] [CrossRef] [PubMed]
[2] Bartalena, L., Piantanida, E., Gallo, D., Lai, A. and Tanda, M.L. (2020) Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy. Frontiers in Endocrinology, 11, Article ID: 615993. [Google Scholar] [CrossRef] [PubMed]
[3] Szelog, J., Swanson, H., Sniegowski, M.C., et al. (2022) Thyroid Eye Disease. Missouri Medicine, 119, 343-350.
[4] Smith, T.J., Cockerham, K., Lelli, G., Choudhary, C., Taylor, S., Barretto, N., et al. (2023) Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States. JAMA Ophthalmology, 141, 159-166. [Google Scholar] [CrossRef] [PubMed]
[5] Cockerham, K.P., Padnick-Silver, L., Stuertz, N., Francis-Sedlak, M. and Holt, R.J. (2021) Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States. Ophthalmology and Therapy, 10, 975-987. [Google Scholar] [CrossRef] [PubMed]
[6] Hoang, T.D., Stocker, D.J., Chou, E.L. and Burch, H.B. (2022) 2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease. Endocrinology and Metabolism Clinics of North America, 51, 287-304. [Google Scholar] [CrossRef] [PubMed]
[7] Yu, C.Y., Ford, R.L., Wester, S.T. and Shriver, E.M. (2022) Update on Thyroid Eye Disease: Regional Variations in Prevalence, Diagnosis, and Management. Indian Journal of Ophthalmology, 70, 2335-2345. [Google Scholar] [CrossRef] [PubMed]
[8] Pouso-Diz, J.M., Abalo-Lojo, J.M. and Gonzalez, F. (2020) Thyroid Eye Disease: Current and Potential Medical Management. International Ophthalmology, 40, 1035-1048. [Google Scholar] [CrossRef] [PubMed]
[9] Bartalena, L. and Tanda, M.L. (2009) Graves’ Ophthalmopathy. New England Journal of Medicine, 360, 994-1001. [Google Scholar] [CrossRef] [PubMed]
[10] Winther, K.H., Rayman, M.P., Bonnema, S.J. and Hegedüs, L. (2020) Selenium in Thyroid Disorders—Essential Knowledge for Clinicians. Nature Reviews Endocrinology, 16, 165-176. [Google Scholar] [CrossRef] [PubMed]
[11] Wu, Q., Rayman, M.P., Lv, H., Schomburg, L., Cui, B., Gao, C., et al. (2015) Low Population Selenium Status Is Associated with Increased Prevalence of Thyroid Disease. The Journal of Clinical Endocrinology & Metabolism, 100, 4037-4047. [Google Scholar] [CrossRef] [PubMed]
[12] Bartalena, L., Kahaly, G.J., Baldeschi, L., et al. (2021) The 2021 European Group on Graves’ Orbitopathy (EUGOGO) Clinical Practice Guidelines for the Medical Management of Graves’ Orbitopathy. European Journal of Endocrinology, 185, G43-G67.
[13] Tanaka, T., Narazaki, M. and Kishimoto, T. (2014) IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology, 6, a016295-a016295. [Google Scholar] [CrossRef] [PubMed]
[14] Moledina, M., Damato, E.M. and Lee, V. (2024) The Changing Landscape of Thyroid Eye Disease: Current Clinical Advances and Future Outlook. Eye, 38, 1425-1437. [Google Scholar] [CrossRef] [PubMed]
[15] Kahaly, G.J., Rösler, H., Pitz, S. and Hommel, G. (2000) Low-versus High-Dose Radiotherapy for Graves’ Ophthalmopathy: A Randomized, Single Blind Trial. The Journal of Clinical Endocrinology & Metabolism, 85, 102-108. [Google Scholar] [CrossRef] [PubMed]
[16] Tanda, M.L. and Bartalena, L. (2012) Efficacy and Safety of Orbital Radiotherapy for Graves’ Orbitopathy. The Journal of Clinical Endocrinology & Metabolism, 97, 3857-3865. [Google Scholar] [CrossRef] [PubMed]
[17] Barbesino, G., Salvi, M. and Freitag, S.K. (2022) Future Projections in Thyroid Eye Disease. The Journal of Clinical Endocrinology & Metabolism, 107, S47-S56. [Google Scholar] [CrossRef] [PubMed]
[18] Kemchoknatee, P., Tangon, D. and Srisombut, T. (2023) A Single-Center Analysis of Visual Outcomes and Associated Factors after Intravenous Methylprednisolone Treatment for Dysthyroid Optic Neuropathy. BMC Ophthalmology, 23, Article No. 32. [Google Scholar] [CrossRef] [PubMed]
[19] Zloto, O., Rosset, A., Priel, A., Landau-Prat, D., Cukierman-Yaffe, T., Shavit, R., et al. (2023) Elevated Serum Thyroid Stimulating Immunoglobulin Linked to Failure of First-Line Intravenous Methylprednisolone Monotherapy in Moderate-to-Severe Thyroid Eye Disease. Eye, 38, 687-690. [Google Scholar] [CrossRef] [PubMed]
[20] Li, H., Wang, B., Li, Q., Li, Q., Qiao, J., Lin, D., et al. (2023) T Cell Subsets Are Associated with Clinical Activity and Efficacy of 4.5 g Intravenous Glucocorticoid for Moderate-to-Severe Thyroid-Associated Ophthalmopathy. Endocrine Research, 48, 55-67. [Google Scholar] [CrossRef] [PubMed]
[21] Wang, Y., Zhang, S., Zhang, Y., Liu, X., Gu, H., Zhong, S., et al. (2018) A Single-Center Retrospective Study of Factors Related to the Effects of Intravenous Glucocorticoid Therapy in Moderate-to-Severe and Active Thyroid-Associated Ophthalmopathy. BMC Endocrine Disorders, 18, Article No. 13. [Google Scholar] [CrossRef] [PubMed]
[22] Park, J., Kim, J., Kim, S.S. and Choi, H. (2023) Prognostic Significance of Thyroid-Stimulating Hormone Receptor Antibodies in Moderate-to-Severe Graves’ Orbitopathy. Frontiers in Endocrinology, 14, Article ID: 1153312. [Google Scholar] [CrossRef] [PubMed]
[23] Hu, S., Wang, Y., He, M., Zhang, M., Ding, X. and Shi, B. (2018) Factors Associated with the Efficacy of Intravenous Methylprednisolone in Moderate‐to‐Severe and Active Thyroid‐Associated Ophthalmopathy: A Single‐Centre Retrospective Study. Clinical Endocrinology, 90, 175-183. [Google Scholar] [CrossRef] [PubMed]
[24] Alkmim, N.R., Rajão, K.M.A.B., Figueiredo, A.R.P., et al. (2024) Predictive Factors for Treatment Response in Active Thyroid Eye Disease. Annales d’Endocrinologie (Paris).

为你推荐